Indacaterol 150 µg

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)Healthy Volunteers

Phase 1

Cardiac Safety of Indacaterol

CompletedNCT01263808

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease, Healthy Volunteers

Start: 2008-04-30Updated: 2010-12-21

Phase 3

Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00792805

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2008-11-30End: 2010-02-28Updated: 2011-08-17

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00821093

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2009-01-31End: 2009-10-31Updated: 2011-08-18

Exacerbation Study

CompletedNCT00845728

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2009-03-31End: 2012-07-31Updated: 2013-11-19

Related Papers

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.

2013-08-21165 citations

Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study.

2011-03-0169 citations